Cargando…
Immunotherapy in Small Cell Lung Cancer
SIMPLE SUMMARY: Small cell lung cancer (SCLC) accounts for about 15% of lung cancers and it has limited therapeutic options and poor prognosis. There has been no real progress for over 30 years in the treatment of this aggressive tumor type and platinum based chemotherapy represented the cornerstone...
Autores principales: | Esposito, Giovanna, Palumbo, Giuliano, Carillio, Guido, Manzo, Anna, Montanino, Agnese, Sforza, Vincenzo, Costanzo, Raffaele, Sandomenico, Claudia, La Manna, Carmine, Martucci, Nicola, La Rocca, Antonello, De Luca, Giuseppe, Piccirillo, Maria Carmela, De Cecio, Rossella, Botti, Gerardo, Totaro, Giuseppe, Muto, Paolo, Picone, Carmine, Normanno, Nicola, Morabito, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565004/ https://www.ncbi.nlm.nih.gov/pubmed/32899891 http://dx.doi.org/10.3390/cancers12092522 |
Ejemplares similares
-
Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
por: Palumbo, Giuliano, et al.
Publicado: (2020) -
RET Inhibitors in Non-Small-Cell Lung Cancer
por: Cascetta, Priscilla, et al.
Publicado: (2021) -
Lurbinectedin in small cell lung cancer
por: Manzo, Anna, et al.
Publicado: (2022) -
Surgery in Small-Cell Lung Cancer
por: Martucci, Nicola, et al.
Publicado: (2021) -
Angiogenesis Inhibitors in Small Cell Lung Cancer
por: Montanino, Agnese, et al.
Publicado: (2021)